Search

Your search keyword '"Buonfanti, G"' showing total 3 results
Start Over Author "Buonfanti, G" Topic breast cancer
3 results on '"Buonfanti, G"'

1. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

Author

Nuzzo, F., Gallo, C., Lastoria, S., Di Maio, M., Piccirillo, M. C., Gravina, A., Landi, G., Rossi, E., Pacilio, C., Labonia, V., Di Rella, F., Bartiromo, A., Buonfanti, G., De Feo, G., Esposito, G., D'Aniello, R., Maiolino, P., Signoriello, S., De Maio, E., and Tinessa, V.

Subjects
*BONE density, *LETROZOLE, *TAMOXIFEN, *ZOLEDRONIC acid, *ADJUVANT treatment of cancer, *CLINICAL trials, *BREAST cancer treatment, *CONFIDENCE intervals
Abstract

Background To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid. Patients and methods A phase 3 trial comparing tamoxifen, letrozole or letrozole + zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients. Two comparisons were planned: letrozole versus tamoxifen and letrozole + zoledronic acid versus letrozole. Primary end point was the difference in 1-year change of T-score at lumbar spine (LTS) measured by dual energy X-ray absorptiometry scan. Results Out of 483 patients enrolled, 459 were available for primary analyses. Median age was 50 (range 28–80). The estimated mean difference (95% confidence interval [CI]) in 1-year change of LTS was equal to −0.30 (95% CI −0.44 to −0.17) in the letrozole versus tamoxifen comparison (P < 0.0001) and to +0.60 (95% CI +0.46 to +0.77) in the letrozole + zoledronic acid versus letrozole comparison (P < 0.0001). Bone damage by letrozole decreased with increasing baseline body mass index in premenopausal, but not postmenopausal, patients (interaction test P = 0.004 and 0.47, respectively). Conclusions In the HOBOE (HOrmonal BOne Effects) trial, the positive effect of zoledronic acid on BMD largely counteracts damage produced by letrozole as compared with tamoxifen. Letrozole effect is lower among overweight/obese premenopausal patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

2. LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of triple negative breast cancer

Author

Marianna Brogna, Francesca Collina, Sabrina Cipolletta, Maurizio Di Bonito, Gabriella Aquino, Michelino De Laurentiis, Monica Cantile, Gerardo Botti, G. Buonfanti, Collina, F., Aquino, G., Brogna, M., Cipolletta, S., Buonfanti, G., De Laurentiis, M., Bonito, M. D., Cantile, M., and Botti, G.

Subjects
0301 basic medicine, Regulation of gene expression, business.industry, HOTAIR, medicine.disease, Metastasis, Androgen receptor, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Oncology, Tumor progression, 030220 oncology & carcinogenesis, Androgen Receptor, medicine, Cancer research, Cancer biomarkers, business, TNBC, Triple-negative breast cancer
Abstract

Triple-negative breast cancers (TNBCs) represent a heterogeneous disease characterized by several molecular subtypes with different prognoses and responses to therapy. For a correct clinical management of TNBC patients the knowledge of the gene regulation mechanisms related to tumor progression and drug response has become fundamental. LncRNAs regulate gene expression through various processes, including chromatin modification, transcription and post-transcription and they are emerging as important cancer biomarkers being involved in tumor pathogenesis, metastatic progression and drug resistance. In this study we aimed to analyze the expression of the lncRNA HOTAIR, mainly involved in breast cancer disease, in a large case series of TNBC patients. We used ISH methods by a RNA probe to better define its staining in tumor tissues and its relation with clinical-pathological parameters and outcomes of patients. Our results show that high HOTAIR expression in tumor tissues is strongly correlated with lymph nodes metastasis (LNM) (p=0.039), as reported also for other tumor types, and has a direct strong association with Androgen Receptor (AR) expression (p= 0.019). These data confirm the prognostic role of HOTAIR in TNBC, and, its involvement in the regulation of AR pathway, suggests the possibility to establish new therapeutic strategies for AR+TNBC patients.

Published
2019

3. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Author

G. Buonfanti, Ciro Gallo, A. De Matteis, Simona Signoriello, Vincenza Tinessa, Alessandro Morabito, F. Perrone, Mauro Piccirillo, Carmen Pacilio, Gennaro Daniele, E. De Maio, M. De Laurentiis, Roberta D’Aniello, G. Botti, Giuseppe Esposito, F. Di Rella, G. Landi, Elisa Rossi, Massimiliano D’Aiuto, M. Di Bonito, Nicola Normanno, G. De Feo, A. Bartiromo, G. Colantuoni, Secondo Lastoria, Piera Maiolino, M. Di Maio, V. Labonia, Pasqualina Giordano, Adriano Gravina, Francesco Nuzzo, Nuzzo, F, Gallo, C, Lastoria, S, Di Maio, M, Piccirillo, Mc, Gravina, A, Landi, G, Rossi, E, Pacilio, C, Labonia, V, Di Rella, F, Bartiromo, A, Buonfanti, G, De Feo, G, Esposito, G, D'Aniello, R, Maiolino, Paola, Signoriello, S, De Maio, E, Tinessa, V, Colantuoni, G, DE LAURENTIIS, Michelino, D'Aiuto, M, Di Bonito, M, Botti, G, Giordano, P, Daniele, G, Morabito, A, Normanno, N, de Matteis, A, Perrone, F., Gallo, Ciro, Maiolino, P, Signoriello, Simona, and De Laurentiis, M

Subjects
Oncology, Adult, medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, Zoledronic Acid, law.invention, Breast cancer, Randomized controlled trial, law, Bone Density, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Humans, Aged, Neoplasm Staging, Bone mineral, Aged, 80 and over, Chemotherapy, Bone Density Conservation Agents, Diphosphonates, Estradiol, business.industry, Letrozole, Imidazoles, Hematology, Middle Aged, Triazoles, medicine.disease, Triptorelin, Tamoxifen, Zoledronic acid, Chemotherapy, Adjuvant, Female, business, medicine.drug
Abstract

BACKGROUND To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid. PATIENTS AND METHODS A phase 3 trial comparing tamoxifen, letrozole or letrozole+zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients. Two comparisons were planned: letrozole versus tamoxifen and letrozole+zoledronic acid versus letrozole. Primary end point was the difference in 1-year change of T-score at lumbar spine (LTS) measured by dual energy X-ray absorptiometry scan. RESULTS Out of 483 patients enrolled, 459 were available for primary analyses. Median age was 50 (range 28-80). The estimated mean difference (95% confidence interval [CI]) in 1-year change of LTS was equal to -0.30 (95% CI -0.44 to -0.17) in the letrozole versus tamoxifen comparison (P

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results